FPL57787对运动诱发性哮喘的影响。

Effect of FPL57787 in exercise-induced asthma.

作者信息

Thomson N C, Green A G, Kerr J W

出版信息

Clin Allergy. 1980 Jan;10(1):43-6. doi: 10.1111/j.1365-2222.1980.tb02078.x.

DOI:10.1111/j.1365-2222.1980.tb02078.x

Abstract

In ten patients with extrinsic asthma the effects of a new oral chromone FPL57787 and placebo were studied in a random double-blind fashion to assess the effect of FPL57787 in preventing exercise-induced asthma (EIA). Exercise testing consisted of steady state running on an inclined treadmill for up to 8 min. FPL57787 gave significant protection (P less 0.01) compared to placebo from the maximum percentage fall in FEV1, FVC and MMEF after exercise. FPL57787 also produced a small but significant (P less than 0.01) percentage increase in FEV1 2 hr after the drug compared to placebo, whereas no significant increase was seen in FVC or in MMEF.

摘要

在10名外源性哮喘患者中，以随机双盲方式研究了一种新型口服色酮FPL57787和安慰剂的效果，以评估FPL57787预防运动诱发性哮喘（EIA）的作用。运动测试包括在倾斜跑步机上持续跑步长达8分钟。与安慰剂相比，FPL57787在运动后FEV1、FVC和MMEF的最大下降百分比方面提供了显著保护（P<0.01）。与安慰剂相比，服用药物2小时后，FPL57787还使FEV1有小幅但显著（P<0.01）的百分比增加，而FVC或MMEF未见显著增加。